Ladies and gentlemen, welcome to the report on the Third Quarter 2025 Conference Call. I am Sandra, the Chorus Call operator.

If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? When we see a declining return on capital employed (ROCE) in conjunction with a declining ...

Fresenius Medical Care said it invested 312 million euros ($367.8 million) to buy out nonphysician investors in its majority-owned Interwell Health kidney-care business, and named a new head for the ...

Fresenius Kabi is expanding its growing biopharma portfolio through a new licensing agreement with Polpharma Biologics S.A. Fresenius Kabi will commercialize Polpharma Biologics’ vedolizumab ...

Fresenius Medical Care AG (ETR:FME) shareholders are probably feeling a little disappointed, since its shares fell 8.0% to €40.92 in the week after its latest interim results. It looks like a pretty ...

Quest Diagnostics completed its acquisition of select assets from Fresenius Medical Care’s laboratory business. As part of the transaction, the Secaucus-based testing provider will now offer ...

Fresenius SE lifted its full-year sales outlook after a strong performance by the German health-care group’s hospitals and Kabi, its biopharma and med tech unit. Organic revenue growth is expected to ...

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that Fresenius infringes either of these patents in district court ...

Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could be negative for the dialysis specialist ...

May 7 (Reuters) - German healthcare group Fresenius (FREG.DE), opens new tab beat analysts' operating profit expectations on Wednesday, driven by a strong performance at its drug making division Kabi ...

Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued a permanent, product-specific billing code for Otulfi (ustekinumab-aauz). Under ...

Fresenius’ operating company Fresenius Kabi reached a global settlement with Amgen concerning their denosumab biosimilars, allowing launch in the U.S. in mid-2025 and in Europe later in H2 of 2025, ...